Dementia Clinical Trials

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

This study is testing an oral investigational study drug in people who have been experiencing a decline in memory function, and/or who have been diagnosed with mild Alzheimer’s disease. The main objective of the study is to see whether this drug can slow the decline in memory and mental functioning ...

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

A research study is evaluating an investigational medication for mild dementia due to Alzheimer’s Disease (AD). This research study may be an option if you or your loved one meet the following criteria: Are at least 50 years of age or older Have a diagnosis of mild dementia due to ...

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.

The main purpose of this study is to evaluate the efficacy of the study drug known as LY3314814 in participants with mild Alzheimer's disease (AD) dementia.

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.

The MISSION-AD study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild cognitive impairment or early Alzheimer's disease. The study drug is a tablet which is taken by mouth once per day. The study will last approximately two years. Eligibility ...